Kylie O'Keefe | executive |
Matthew Klein | executive |
Eric Pauwels | executive |
Emily Hill | executive |
Kristen Kluska | analyst |
Eric Joseph | analyst |
Robyn Karnauskas | analyst |
Joseph Thome | analyst |
Dingding Shi | analyst |
Danielle Brill | analyst |
Will Soghikian | analyst |
Lee Hung | analyst |
Huidong Wang | analyst |
Yihan Li | analyst |
Cade Kruse | analyst |
Good day, and thank you for standing by, and welcome to the PTC First Quarter 2023 Financial Results Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the call over to Kylie O'Keefe, Chief Commercial Officer.
You may begin.
Good afternoon, and thank you for joining us today to discuss PTC Therapeutics First Quarter 2023 Corporate Update and Financial Results. I am joined today by our Chief Executive Officer, Matthew Klein; our Chief Business Officer, Eric Pauwels; and our Chief Financial Officer, Emily Hill. Today's call will include forward-looking statements based on our current expectations.